Literature DB >> 18800255

Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles.

Shirzad Azarmi1, Raimar Lobenberg, Wilson H Roa, Shusheng Tai, W H Finlay.   

Abstract

The purpose of this study was to evaluate the safety of a new inhalable effervescent carrier preparation containing model nanoparticles. Spray-freeze drying was used to prepare inhalable powders containing butylcyanoacrylate nanoparticles. The particle size of the nanoparticles before incorporation into the effervescent carrier and after dissolving the carrier powder was measured using laser light scattering. The particle size distribution of the effervescent carrier aerosol particles was measured using a cascade impactor. The prepared powder was tested in vivo using five Balb/c nude mice. The animals were treated with 1 mg of inhalable powder every week for 4 weeks. The body weight and morbidity score of the mice were observed over an 8-week period. The effervescent activity of the inhalable nanoparticle powder was observed when the powder was exposed to humidity. The particle size of the nanoparticles did not change significantly after spray-freeze drying. The mass median aerodynamic diameter (MMAD) of the prepared powder was 4.80 +/- 2.12 microm, which is suitable for lung delivery. The animals that were treated with effervescent powder tolerated the administration without any changes in their morbidity scores. Our pilot study demonstrates that pulmonary nanoparticle delivery via effervescent carrier particles appears safe in the present animal model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800255     DOI: 10.1080/03639040802149079

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  6 in total

1.  Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation.

Authors:  M H D Kamal Al-Hallak; Shirzad Azarmi; Chris Sun; Patrick Lai; Elmar J Prenner; Wilson H Roa; Raimar Löbenberg
Journal:  AAPS J       Date:  2010-04-20       Impact factor: 4.009

2.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

3.  Pulmonary Delivery of Magnetically Targeted Nano-in-Microparticles.

Authors:  Amber A McBride; Dominique N Price; Pavan Muttil
Journal:  Methods Mol Biol       Date:  2017

4.  Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes.

Authors:  Qiu Zhong; Dakshina Murthy Devanga Chinta; Sarala Pamujula; Haifan Wang; Xin Yao; Tarun K Mandal; Ronald B Luftig
Journal:  J Nanobiotechnology       Date:  2010-02-24       Impact factor: 10.435

Review 5.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 6.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.